top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
iScreen Shoter - 20261028172009135.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
Frame 1000008569.png
Frame 1000008568.png
4acc1a9d-ced8-4f58-a79e-cd2ac6fe752e.png
Liver Attenuation.png
Frame 1000008251.jpg
Lung LAI.jpg
lung HAI.jpg
ٍEpicardial Fat .png
coronaryArteryCalcification.png
Thoracic Aorta and Pulmonary Artery Sizing .png
iScreen Shoter - 20261028184534618.jpg
Cardiac Chambers Volumetry.png
iScreen Shoter - 20261028184548151.jpg
aortic.jpg

Long-Term Risk Prediction and Detection of Aortic Stenosis From AI-Quantified Multisite Calcification on Noncontrast CT: An AI-CVD Analysis of MESA

4 hours ago
2 min read

Submitted manuscript | Original research review

Aortic stenosis (AS) can remain clinically silent until advanced disease, while structural changes may begin earlier. This MESA-focused study evaluated whether AI-derived cardiovascular phenotypes measured on noncontrast cardiac CT are associated with incident AS and can improve long-term prediction, alongside a separate model for AS detection.

Study design

The prediction analysis included 5,520 MESA participants with baseline noncontrast cardiac CT. Incident AS was identified through adjudicated events and Exam 6 echocardiography. Researchers assessed associations using multivariable Cox models and internally validated a random survival forest with nested cross-validation. A separate detection model was developed in 1,857 MESA Exam 6 participants with paired CT and echocardiography, then externally evaluated in the Framingham Heart Study.

Key findings

During a median 16.7 years of follow-up, 157 participants developed AS. Aortic valve calcium showed the strongest association with incident disease (hazard ratio per standard-deviation increase, 4.34; 95% CI, 3.33-5.66). At 10 years, the AI-CVD model using age, sex, aortic valve calcium, mitral valve calcium, and thoracic aortic calcification achieved an AUROC of 0.973, compared with 0.809 for a model based on routinely measured clinical factors. The corresponding AUPRC values were 0.256 and 0.024. In external validation, the detection model achieved an AUROC of 0.946, sensitivity of 87.8%, and specificity of 94.5%.

Interpretation

These findings suggest that AI-based quantification of multisite calcification on noncontrast CT may help identify long-term AS risk and detect existing disease. The prediction model was internally validated and the detection model externally assessed; prospective evaluation is still needed to establish performance and clinical impact in routine care.

Abstract

Background: Aortic stenosis may remain silent until severe. Objective: To assess whether AI-derived cardiovascular phenotypes from noncontrast CT are associated with incident AS and can predict and detect disease. Methods: In 5,520 MESA participants, incident AS associations were analyzed and an AI-CVD prediction model was evaluated using nested cross-validation. A separate detection model was developed in 1,857 MESA participants and externally evaluated in Framingham. Results: Over median 16.7-year follow-up, 157 participants developed AS. Aortic valve calcium had the strongest association (HR 4.34; 95% CI 3.33-5.66). The 10-year AUROC was 0.973 for the AI-CVD model vs 0.809 for the clinical model; external detection AUROC was 0.946 (sensitivity 87.8%, specificity 94.5%). Conclusions: Automated CT phenotyping may support scalable prediction and detection of AS.

Status: Submitted manuscript. The full manuscript is not attached.

Download the abstract

Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png

©2026 HeartLung Corporation. All Rights Reserved. U.S. Patent Nos. 12,620,494; 12,599,350; 11,610,686. Licensed U.S. Patent Nos. 9,119,590 and 10,695,022. U.S. Patent Applications Pending: 19/390,544; 19/403,750; 19/643,672; 19/728,738; 19/741,766; 18/652,123; 18/771,542; 19/390,629; 19/417,345; 19/467,802; 19/565,385; 19/682,416; 19/690,066. International PCT Applications: PCT/US2025/058510; PCT/US2025/061047; PCT/US2025/058505; PCT/US2026/013566; PCT/US2026/024304. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoLiver, AutoChamber, AutoLung and other product names and trademarks displayed on this website are protected by applicable intellectual property laws. All rights reserved.

bottom of page